One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
On the Shoulders of Giants — From Jenner’s Cowpox to mRNA Covid Vaccines
Angela Desmond, M.D., Ph.D., and Paul A. Offit, M.D.
doi : 10.1056/NEJMp2034334
N Engl J Med 2021; 384:1081-1083
Addressing Workforce Diversity — A Quality-Improvement Framework
Lisa S. Rotenstein, M.D., M.B.A., Joan Y. Reede, M.D., M.P.H., M.B.A., and Anupam B. Jena, M.D., Ph.D.
doi : 10.1056/NEJMp2032224
N Engl J Med 2021; 384:1083-1086
The Good Fit — Why Medical Applicants’ Personal Statements Are Anything but Personal
Michelle H. Silver, M.D.
doi : 10.1056/NEJMp2032383
N Engl J Med 2021; 384:1086-1087
Medicare’s New Device-Coverage Pathway — Breakthrough or Breakdown?
Vinay K. Rathi, M.D., M.B.A., James L. Johnston, B.S., Joseph S. Ross, M.D., M.H.S., and Sanket S. Dhruva, M.D., M.H.S.
doi : 10.1056/NEJMp2101874
N Engl J Med 2021; 384:e43
Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120–MF59 in Adults
Glenda E. Gray, M.B., B.Ch., Linda-Gail Bekker, M.B., Ch.B., Ph.D., Fatima Laher, M.B., B.Ch., Mookho Malahleha, M.B., Ch.B., M.P.H., Mary Allen, B.S.N., M.S., Zoe Moodie, Ph.D., Nicole Grunenberg, M.D., Yunda Huang, Ph.D., Doug Grove, M.S., Brittany Prigmore, M.S., Jia J. Kee, M.S., David Benkeser, Ph.D., John Hural, Ph.D., Craig Innes, M.B., Ch.B., Erica Lazarus, M.B., Ch.B., Graeme Meintjes, M.B., Ch.B., M.P.H., Ph.D., Nivashnee Naicker, M.B., Ch.B., M.P.H., Dishiki Kalonji, M.B., B.Ch., Maphoshane Nchabeleng, M.B., Ch.B., Modulakgotla Sebe, M.B., Ch.B., Nishanta Singh, M.B., Ch.B., Philip Kotze, M.B., Ch.B., Sheetal Kassim, M.B., Ch.B., Thozama Dubula, M.Med., Vimla Naicker, M.B., Ch.B., William Brumskine, M.B., Ch.B., Cleon N. Ncayiya, B.Sc., Amy M. Ward, M.B., B.Ch., Nigel Garrett, M.B., B.S., Ph.D., Girisha Kistnasami, B.Sc., Zakir Gaffoor, M.Sc., Pearl Selepe, M.B., Ch.B., Philisiwe B. Makhoba, M.B., Ch.B., Matsontso P. Mathebula, M.B., Ch.B., M.P.H., Pamela Mda, M.B., Ch.B., M.Med., Tania Adonis, B.Psych., Katlego S. Mapetla, B.Tech., Bontle Modibedi, R.N., Tricia Philip, M.B., Ch.B., Gladys Kobane, R.N., Carter Bentley, Ph.D., Shelly Ramirez, M.A., Simbarashe Takuva, M.B., Ch.B., Megan Jones, B.S.N., M.P.H., Mpho Sikhosana, M.B., B.Ch., M.P.H., Millicent Atujuna, Ph.D., Michele Andrasik, Ph.D., Nima S. Hejazi, M.A., Adrian Puren, M.B., B.Ch., Ph.D., Lubbe Wiesner, Ph.D., Sanjay Phogat, Ph.D., Carlos Diaz Granados, M.D., Marguerite Koutsoukos, M.Sc., Olivier Van Der Meeren, M.D., Susan W. Barnett, Ph.D., Niranjan Kanesa-Thasan, M.D., James G. Kublin, M.D., M.P.H., M. Juliana McElrath, M.D., Ph.D., Peter B. Gilbert, Ph.D., Holly Janes, Ph.D., and Lawrence Corey, M.D. for the HVTN 702 Study Team*
doi : 10.1056/NEJMoa2031499
N Engl J Med 2021; 384:1089-1100
A safe, effective vaccine is essential to eradicating human immunodeficiency virus (HIV) infection. A canarypox–protein HIV vaccine regimen (ALVAC-HIV plus AIDSVAX B/E) showed modest efficacy in reducing infection in Thailand. An analogous regimen using HIV-1 subtype C virus showed potent humoral and cellular responses in a phase 1–2a trial in South Africa. Efficacy data and additional safety data were needed for this regimen in a larger population in South Africa.
Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis
Thomas Bieber, M.D., Ph.D., Eric L. Simpson, M.D., Jonathan I. Silverberg, M.D., Ph.D., M.P.H., Diamant Thaçi, M.D., Carle Paul, M.D., Ph.D., Andrew E. Pink, Ph.D., Yoko Kataoka, M.D., Chia-Yu Chu, M.D., Ph.D., Marco DiBonaventura, Ph.D., Ricardo Rojo, M.D., Jeremias Antinew, M.D., Ileana Ionita, Ph.D., Rodney Sinclair, M.D., Seth Forman, M.D., Jacek Zdybski, M.D., Pinaki Biswas, Ph.D., Bimal Malhotra, Ph.D., Fan Zhang, Ph.D., and Hernan Valdez, M.D. for the JADE COMPARE Investigators*
doi : 10.1056/NEJMoa2019380
N Engl J Med 2021; 384:1101-1112
The oral Janus kinase 1 (JAK1) inhibitor abrocitinib, which reduces interleukin-4 and interleukin-13 signaling, is being investigated for the treatment of atopic dermatitis. Data from trials comparing JAK1 inhibitors with monoclonal antibodies, such as dupilumab, that block interleukin-4 receptors are limited.
A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis
Philip N. Newsome, M.B., Ch.B., Ph.D., Kristine Buchholtz, M.D., Ph.D., Kenneth Cusi, M.D., Martin Linder, M.Sc., Takeshi Okanoue, M.D., Ph.D., Vlad Ratziu, M.D., Ph.D., Arun J. Sanyal, M.D., Anne-Sophie Sejling, M.D., Ph.D., and Stephen A. Harrison, M.D. for the NN9931-4296 Investigators*
doi : 10.1056/NEJMoa2028395
N Engl J Med 2021; 384:1113-1124
Nonalcoholic steatohepatitis (NASH) is a common disease that is associated with increased morbidity and mortality, but treatment options are limited. The efficacy and safety of the glucagon-like peptide-1 receptor agonist semaglutide in patients with NASH is not known.
Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma
Thomas Powles, M.D., Jonathan E. Rosenberg, M.D., Guru P. Sonpavde, M.D., Yohann Loriot, M.D., Ph.D., Ignacio Dur?n, M.D., Ph.D., Jae-Lyun Lee, M.D., Ph.D., Nobuaki Matsubara, M.D., Christof Vulsteke, M.D., Ph.D., Daniel Castellano, M.D., Chunzhang Wu, Ph.D., Mary Campbell, M.D., Maria Matsangou, M.B., Ch.B., M.D., and Daniel P. Petrylak, M.D.
doi : 10.1056/NEJMoa2035807
N Engl J Med 2021; 384:1125-1135
Patients with advanced urothelial carcinoma have poor overall survival after platinum-containing chemotherapy and programmed cell death protein 1 (PD-1) or programmed death ligand 1 (PD-L1) inhibitor treatment.
Intranasal Naloxone Administration
Rafael Ortega, M.D., Ala Nozari, M.D., Ph.D., William Baker, M.D., Sannoor Surani, M.D., and Melinda Edwards, M.D.
doi : 10.1056/NEJMvcm2020745
N Engl J Med 2021; 384:e44
Strawberry Tongue in Streptococcal Pharyngitis
Monalisa Sahu, M.B., B.S., M.D., D.M., and Pradipt R. Sahoo, M.B., B.S.
doi : 10.1056/NEJMicm2026930
N Engl J Med 2021; 384:1144
Kartagener’s Syndrome
Kenneth Zurcher, M.D., and Akira Kawashima, M.D., Ph.D.
doi : 10.1056/NEJMicm2028152
N Engl J Med 2021; 384:e45
Case 9-2021: A 16-Year-Old Boy with Headache, Abdominal Pain, and Hypertension
Kristian R. Olson, M.D., M.P.H., Katherine Nimkin, M.D., Ryan W. Carroll, M.D., M.P.H., Nikolas Stathatos, M.D., and Zehra Ordulu, M.D.
doi : 10.1056/NEJMcpc2027094
N Engl J Med 2021; 384:1145-1155
Audio Interview: What Earlier Epidemics Teach Us about Covid-19
Eric J. Rubin, M.D., Ph.D., Lindsey R. Baden, M.D., Allan M. Brandt, Ph.D., and Stephen Morrissey, Ph.D.
doi : 10.1056/NEJMe2105030
N Engl J Med 2021; 384:e55
Doctor, How Long Should I Isolate?
Siri R. Kadire, M.D., Valeria Fabre, M.D., and Richard P. Wenzel, M.D.
doi : 10.1056/NEJMclde2100910
N Engl J Med 2021; 384:e47
Obesity, Immunity, and Cancer
Jeffrey C. Rathmell, Ph.D.
doi : 10.1056/NEJMcibr2035081
N Engl J Med 2021; 384:1160-1162
Embracing Genetic Diversity to Improve Black Health
Akinyemi Oni-Orisan, Pharm.D., Ph.D., Yusuph Mavura, M.S., Yambazi Banda, Ph.D., Timothy A. Thornton, Ph.D., and Ronnie Sebro, M.D., Ph.D.
doi : 10.1056/NEJMms2031080
N Engl J Med 2021; 384:1163-1167
The Spectrum of Benefit from Checkpoint Blockade in Hypermutated Tumors
doi : 10.1056/NEJMc2031965
N Engl J Med 2021; 384:1168-1170
Monoclonal Antibody for Patients with Covid-19
doi : 10.1056/NEJMc2100221
N Engl J Med 2021; 384:1170-1171
Drug-Coated Balloons for Dysfunctional Dialysis Arteriovenous Fistulas
doi : 10.1056/NEJMc2031782
N Engl J Med 2021; 384:1171-1174
Olaparib in Metastatic Castration-Resistant Prostate Cancer
doi : 10.1056/NEJMc2100225
N Engl J Med 2021; 384:1174-1176
Systemic Therapy for Estrogen Receptor–Positive, HER2-Negative Breast Cancer
doi : 10.1056/NEJMc2101282
N Engl J Med 2021; 384:1176-1177
Uhambo — Twists and Turns on the Journey to an Efficacious HIV-1 Vaccine
Mark B. Feinberg, M.D., Ph.D.
doi : 10.1056/NEJMe2102358
N Engl J Med 2021; 384:1157-1159
